Among 16 patients with this difficult-to-treat tumor "with few treatment options," the confirmed overall response rate (ORR) ...

The ability of immune cells—particularly CD8+ T cells—to launch a rapid burst of proliferation inside tumors is key to the ...

Some 68% of patients with autoimmune disease had "major" side effects from CAR-T therapy for myeloma, lymphoma, or leukemia, ...

So far, immune cells that have been engineered to kill cancers, known as CAR T-cells, haven’t worked well against solid ...

Even for a newly minted Nobel laureate, downtime is hard to find. | Even for a newly minted Nobel laureate, downtime is hard ...

T cells play central roles in the adaptive immune response against cancer. Their functional inactivation is a primary driver of tumor progression, making the reactivation of T cell function a main ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

In 2015, Bluestone led a small clinical trial to isolate and grow Tregs from diabetes patients and then reinfuse the cells ...

Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...